Industry & Business

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site

 Breaking News
  • New ‘Erasmus Student Network’ booking platform launched at Ryanair Ryanair has launched a new dedicated booking platform in partnership with Erasmus Student Network, offering Erasmus students fare discounts, free bags and tailored travel offers. Delivered as part of Year 4 of Ryanair’s “Always Getting Better” programme, this partnership offers Erasmus students a dedicated ESN booking platform where they can avail of: 15% flight discounts on the [...]...
  • Thermo King manufacturing facility in Galway with zero waste to landfill The Galway manufacturing facility of Thermo King, a manufacturer of transport temperature control solutions for a variety of mobile applications and a brand of Ingersoll Rand, has become one of the first Ingersoll Rand sites to manage zero waste to landfill. The sustainability push in the Thermo King Galway factory builds on the Ingersoll Rand Climate Commitment made [...]...
  • Irish SME develops app to help students connect with colleges Irish start-up StudyBundles has developed an app that helps CAO applicants connect with third-level institutions while they are deciding which college to attend. The CampusConnect app benefits students as they become immersed in college life before they step foot on campus, making the transition easier. For colleges and universities it helps them to convert student [...]...
  • Lack and cost of accommodation biggest problem for tech firms While staff retention was the primary difficulty for Digital and Technology companies in 2016, this has become secondary to the fastest emerging problem in 2017 – the lack and the cost of accommodation. According to the latest market analysis and salary survey by recruitment group Prosperity, the enduring reality is that the Digital and Tech [...]...
  • Private data exchange between businesses forecasted to be six times volume of public internet by 2020 – Equinix Equinix, Inc., the global Interconnection and data centre company, has announced that Bandwidth used in private data exchange between businesses is expected to be six times that of the public internet by 2020. The insights come from the Global Interconnection Index, a new market study published by Equinix. The Index found that Interconnection Bandwidth is outpacing growth of the public [...]...

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site
June 01
09:00 2017

Takeda Pharmaceutical Company Limited has announced that a groundbreaking ceremony has been held for its new production facility at the existing Grange Castle site in Ireland. Takeda’s existing footprint at the Grange Castle site will be expanded with the construction of a new standalone, high-containment production facility dedicated to manufacturing its oncology product NINLARO for global markets. The investment will create approximately 40 new jobs over the next two years.

“Our new plant in Grange Castle, Ireland is a strategic investment for Takeda,” said Thomas Wozniewski, Head of Global Manufacturing & Supply. “It will give us the crucial in-house manufacturing capacity to meet the increasing demand for our innovative product NINLARO.”

The construction of the plant, which begins in June 2017, will be managed by Project Management Group with over €40 million investment in total. The plant is scheduled to be completed in Q2 FY18 and become operational to commence shipment of secondary packaged product in the second half of FY18.

The new production facility will be unique in that it will house the Drug Substance, Drug Product, Primary and Secondary Packaging and QC processes all under one roof.

NINLARO was approved in November 2015 by the U.S. Food and Drug Administration (FDA). It is the first and only once-weekly oral proteasome inhibitor launched in the U.S. for the treatment of patients with multiple myeloma who have received at least one prior therapy, enabling an all-oral proteasome inhibitor-based triplet treatment regimen for the first time. Additionally, NINLARO® was approved by the Japanese Ministry of Health, Labour and Welfare in March 2017 and launched in May as the first oral proteasome inhibitor in Japan, indicated in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma.

About Author

editor

editor

Related Articles






Advertisements

































National Manufacturing Conference & Exhibition 2016

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4

Join our Newsletter!



By subscribing you agree to receive updates from us by email. You can opt out of receiving emails at any time.